Clinical trial
Study Evaluating HKI-272 Administered to Healthy Subjects
NCT00366600 · Puma Biotechnology, Inc., Industry · Completed
Key facts
| NCT number | NCT00366600 |
|---|---|
| Title | Study Evaluating HKI-272 Administered to Healthy Subjects |
| Official title | Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Healthy Subjects. |
| Lead sponsor | Puma Biotechnology, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | neratinib |
| Enrollment | 56 |
| Start date | Jul 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Aug 21, 2006 |
| Last update posted | Sep 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: